Bita Afshari-Rostami
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Authors' Response to "Comment on 'SMPDL3B as a novel biomarker and therapeutic target in myalgic encephalomyelitis'".
Journal: Journal of translational medicine
Published: December 02, 2025
PTPRN2 hypomethylation and PHB2-associated miR-153-3p maturation define dual epigenetic features linked to symptom variability in Myalgic encephalomyelitis.
Journal: Journal of translational medicine
Published: December 02, 2025
Correction: SMPDL3B a novel biomarker and therapeutic target in myalgic encephalomyelitis.
Journal: Journal of translational medicine
Published: August 14, 2025
Circulating Levels of SMPDL3B Define Metabolic Endophenotypes and Subclinical Kidney Alterations in Myalgic Encephalomyelitis.
Journal: International journal of molecular sciences
Published: July 22, 2025
Haptoglobin phenotypes and structural variants associate with post-exertional malaise and cognitive dysfunction in myalgic encephalomyelitis.
Journal: Journal of translational medicine
Published: May 31, 2025
UBC9-Mediated SUMO Pathway Drives Prohibitin-1 Nuclear Accumulation and PITX1 Repression in Primary Osteoarthritis.
Journal: International journal of molecular sciences
Published: May 29, 2025
SMPDL3B a novel biomarker and therapeutic target in myalgic encephalomyelitis.
Journal: Journal of translational medicine
Published: April 10, 2025
Circulating microRNA expression signatures accurately discriminate myalgic encephalomyelitis from fibromyalgia and comorbid conditions.
Journal: Scientific reports
Published: April 29, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026